24 results about "PLT - Platelets" patented technology

The application discloses a platelet performance index evaluation method and device. The method comprises the following steps: collecting platelets to be detected; collecting cloud and mist characteristic data of the platelets to be detected by using an image and video device, wherein the cloud and mist characteristic data comprises cloud and mist characteristic image data and / or cloud and mist characteristic video data; and evaluating platelet performance indexes by using the cloud and mist characteristic data of the platelets to be detected. The application can accurately, quickly and at low cost detect platelet performance indexes, and solves problems of long time consumption, high cost and large result error of a traditional platelet performance detection method.

The utility model relates to the field of biomedical technology, concretely is a kind of platelet-rich plasma preparation device.The device includes storage tube, sealing cover and piston assembly.Storage tube is divided into storage part and injection part, and stop structure is arranged in storage cavity;Sealing cover is in interference fit with injection part and can be punctured, and closed blood sampling is realized in combination with vacuum negative pressure cavity.Piston assembly realizes locking and release by the cooperation of elastic movable head and stop structure, ensures that each blood layer is independently pushed after centrifugal stratification, and avoids cross contamination.Storage tube is made of transparent material and is provided with scale, so that stratification state and accurate separation can be observed.The device is integrated with blood sampling, centrifugation and extraction functions, and PRP preparation can be completed through single centrifugation and push-pull piston, which is convenient to operate and high in efficiency.The utility model solves the problems of complex operation, low separation efficiency and easy pollution of traditional method, and significantly improves the reliability and practicality of PRP preparation.

This invention provides a means to obtain more clinically useful information when analyzing particles contained in blood samples using metachromatic positive dyes. In a particle analysis method for analyzing particles contained in blood samples, particles are stained with a metachromatic positive dye; the stained particles are irradiated with light; the intensity of a first fluorescence from the stacking component of the metachromatic positive dye and the intensity of a second fluorescence from the embedded component of the metachromatic positive dye are measured, the first and second fluorescence being emitted by each particle contained in the blood sample; the intensities of the first and second fluorescence emitted by each particle are normalized according to the size of each particle to obtain the fluorescence concentration of each of the first and second fluorescence in each particle; in a two-dimensional plot of the normalized fluorescence concentrations, each particle is clustered into multiple particle clusters, including at least two of erythrocyte clusters, platelet clusters, and nucleated cell clusters; and a histogram is created where the intensity of the first fluorescence is a histogram of the RNA amount of the class and the intensity of the second fluorescence is a histogram of the DNA amount of the class included in at least one of the multiple particle clusters.

The present application relates to the technical field of platelet aggregation detection, and specifically discloses a clinical platelet aggregation detection carrier, which comprises an instrument body and further comprises: a detection assembly arranged inside the instrument body, which is used for detecting different types of samples of lipemia, anemia and normal blood and selecting centrifugal operation of the blood samples; the detection assembly can detect different types of samples of lipemia, anemia and normal blood, and can automatically indicate whether centrifugal operation of the blood is needed according to the types of the detected samples; through the sampling assembly, the blood samples at different layer depths can be automatically adjusted according to the lipemia, anemia and normal blood samples detected by the detection assembly; through the agent adding assembly, the amount of the added inducing agent can be automatically adjusted according to the sample amount taken by the sampling assembly, so that the concentration of the mixed inducing agent reaches the specified range, thereby improving the detection accuracy of the platelet aggregation degree.

1. Name of the product in this design: Blood separation device. 2. Application of this design: This design is used for centrifugation of blood to prepare platelet-rich plasma. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention relates to the interdisciplinary field of biomedical detection and Internet of Things (IoT) sensing technology, specifically disclosing a platelet-rich plasma concentration detection system based on IoT biosensors. The system includes a microfluidic sensor chip, a multi-frequency electrochemical impedance spectroscopy (MES) acquisition unit, a cell morphology identification module, an IoT communication unit, and a remote data processing server. It monitors platelet dynamic aggregation in real time through a three-electrode system, and combines high-dimensional features of broadband impedance spectroscopy with a pre-trained convolutional neural network model to accurately distinguish between simple platelet aggregates, platelet-leukocyte complexes, and microthrombus structures. Furthermore, it leverages the IoT architecture to complete encrypted data upload, remote model optimization, and intelligent coagulation risk assessment. Through the above technical solutions, this invention improves the sensitivity, specificity, and clinical applicability of the detection, constructing a closed-loop blood monitoring system from bedside detection to cloud-based decision support.

The embodiments of the present application relate to a platelet counting method and a blood cell analyzer. The method comprises: aspirating a blood sample to be tested; mixing one portion of said blood sample with a diluent to prepare a first test sample, and mixing the other portion of said blood sample with a hemolytic agent and fluorescent dye to prepare a second test sample; performing impedance measurement on the first test sample, in order to obtain an electrical signal of the first test sample; performing optical measurement on the second test sample, in order to obtain at least one optical signal from among a scattered light signal and a fluorescent light signal of the second test sample; at least on the basis of the electrical signal of the first test sample, obtaining platelet distribution information of said blood sample; and at least on the basis of the pulse width of an optical signal among the at least one optical signal that corresponds to platelets in the second test sample, and the platelet distribution information, obtaining a platelet count value. Thus, an accurate platelet count can be obtained at a low cost.

This invention discloses a predictive model for early fever and infection after CAR-T therapy. The equation for this predictive model is: P = 1 / (1 + e^(-3.23 + 0.017 × CRP + 0.003 × IL - 6 - 0.023 × platelet count - 8.048 × lymphocyte count - 1.241 × FCV + 1.6146 × neutropenia grade)); where P is the probability of infection. P < 0.20 is defined as low risk, classified as CRS; 0.2 ≤ P ≤ 0.6 is defined as medium risk, requiring further testing to determine whether it is infection or CRS; P > 0.6 is defined as high risk, classified as infection. This predictive model is used to predict the likelihood of infection in the first fever event after CAR-T therapy. By analyzing various clinical laboratory indicators and combining logistic regression analysis, the model screens out key predictive factors related to infection risk, ultimately establishing an efficient and easy-to-use predictive tool. This model can effectively predict the occurrence of infection, provide clinicians with guidance for early intervention, reduce unnecessary clinical testing, and optimize patients' treatment plans.

This invention provides a platelet counting method that enables highly sensitive and stable platelet counting even after a significant amount of time has passed since blood collection. [Solution] A platelet counting method comprising bringing a collected blood sample 20 into contact with a substrate 12 having a platelet-solid phase portion 14 on its surface, and washing the substrate 12 to which the blood sample 20 has adhered while the platelets 26 contained in the blood sample 20 are solidified on the substrate 12.

This invention relates to the field of medical device technology, and particularly to a centrifuge adapted for the preparation of centrifuge tubes for clinical cell mitochondrial extraction. The centrifuge includes: a centrifuge body, a centrifuge lid hinged to one side of the centrifuge body, a platelet detection device fixedly disposed on the side of the centrifuge lid away from the centrifuge body, and a liquid aspiration device rotatably disposed on the side of the centrifuge lid near the centrifuge body. A lid locking mechanism is fixedly disposed on the side of the centrifuge body near the centrifuge lid, and a locking hook is fixedly disposed on the side of the centrifuge lid near the centrifuge body, the locking hook matching the lid locking mechanism. This invention avoids the variability caused by human operation during multiple supernatant extractions, reduces the possibility of contamination from human operation, ensures the sterility and component stability of the extraction process, and greatly improves the efficiency and success rate of mitochondrial extraction.

The application discloses a magnetic suspension pulse counterpulsation extracorporeal membrane oxygenation system and a control method thereof, and belongs to the technical field of medical equipment. The system comprises a magnetic suspension blood pump, an oxygenator, a blood pump controller, and an electrocardio and pulse signal acquisition and analysis unit, which continuously collects electrocardiogram data and arterial pressure waveform data of a patient in a predetermined window period to form original data packets with time stamps. The electrocardio and pulse signal acquisition and analysis unit is used for collecting electrocardio signals and / or arterial pressure waveform signals of the patient in real time. The application simulates the hemodynamic effect of in-vivo balloon counterpulsation through the rotation speed control of the extracorporeal magnetic suspension blood pump, realizes pulsatile perfusion synchronized with the heart cycle, solves the problem of increased afterload caused by non-pulsatile blood flow of a traditional extracorporeal membrane oxygenation system, and fundamentally eliminates the risks of hemolysis, platelet destruction, thrombosis and vascular injury caused by the in-vessel balloon.

1. The name of the design product: platelet-rich plasma (PRP) auxiliary extraction device. 2. The use of the design product: a device for assisting a centrifuge in separating blood to obtain platelet-rich plasma. 3. The design points of the design product: the shape, pattern and their combination of the product. 4. The picture or photo that best indicates the design points: perspective view.

The disclosure relates to a sample analysis system and a platelet abnormality detection method. The sample analysis system includes: a blood cell analysis device including a sample preparation portion and a detection portion, the sample preparation portion being configured to prepare a test sample from a blood sample to be tested, and the detection portion being configured to perform a test on the test sample to obtain a first platelet test result; a smear preparation device configured to prepare a sample smear to be tested from the blood sample to be tested; a cell image acquisition device configured to image the sample smear to be tested to obtain cell images of the blood sample to be tested, and analyze the cell images to obtain a second platelet test result; and a data processing device configured to determine whether a platelet abnormality is present in the blood sample to be tested, based on the first platelet test result and the second platelet test result, and output a platelet abnormality prompt in response to determining that the platelet abnormality is present. This allows for more accurate identification of the platelet abnormality.

The present disclosure relates to the field of biomedical technology, and specifically relates to a reagent combination, kit and detection method for detecting platelet activation marker PAC-1. The reagent combination comprises: a first detection probe, a second detection probe, a third detection probe and a fourth detection probe; the first detection probe is formed by at least conjugating a DNA1 and a PAC-1 antibody 1; the second detection probe is formed by at least conjugating a PAC-1 antibody 2 and a DNA2; the third detection probe is a DNA3 labeled with a fluorescent molecule; the fourth detection probe is an antioxidant bound to a carrier molecule. When the reagent combination or kit of the present disclosure is used to detect PAC-1, the cost is relatively low and whole blood can be used for detection, which allows for convenience and speed while avoiding artificial platelet activation in in vitro samples; moreover, the detection operation procedure is simple and the overall detection time is relatively short, making the invention suitable for the actual needs of clinical detection of PAC-1.

The application discloses an AI fusion enabled CRRT intelligent anticoagulation decision system, and relates to the technical field of intelligent control of medical equipment.The system comprises a data acquisition module, a data preprocessing module, an AI calculation module, a decision output module and a control interface module.The application constructs a hybrid AI model with fusion space and time sequence feature extraction capability, realizes multidimensional and dynamic precise modeling of the complex problem of CRRT anticoagulation decision, uses a convolutional neural network (CNN) to mine deep spatial correlation features among patient weight, coagulation indicators and platelet count static parameters, simultaneously uses a long short-term memory network (LSTM) to process high-frequency time sequences formed by transmembrane pressure and filter pressure machine parameters, and learns dynamic rules of filter performance attenuation and subtle trends of coagulation precursors from the time sequences, so that the system can generate an optimal parameter trajectory that is self-adaptively adjusted with the evolution of the system state based on the current instantaneous system state.

The present invention relates to a method for diagnosing the risk of non-alcoholic steatohepatitis (NAS) in a human patient with a metabolic disorder, comprising: (i) calculating a non-alcoholic fatty liver disease (NFD) score from the patient's age, body mass index (BMI), aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ratio, platelet count, and hyperglycemic status; and (ii) calculating a non-alcoholic steatohepatitis score (NIS4) for the patient based on the levels of hsa-miR-34a-5p, alpha-2-macroglobulin (A2M), YKL-40, and glycosylated hemoglobin (HbA1c), measured in a blood sample or blood derivative from the patient; and determining the presence or absence of NAS risk in the patient based on these scores. where the NFS test is implemented before or after the NIS4 test.

1. Name of the product in this design: Ultrasonic Guided Wave Thromboplastin Detector. 2. Purpose of this design: For the detection of coagulation and fibrinolysis processes and platelets. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key features: the front view.

This application provides a molecular marker in the bovine CSAD gene and its application. The molecular marker is one or more of g.26839616 T>C and g.26842339 C>T in the bovine genome. The molecular marker provided in this application, or the substance used to detect single nucleotide polymorphisms in bovine molecular markers, can be used in bovine genetic breeding to increase platelet count in Tibetan improved cattle offspring and solve the hypoxia bottleneck problem faced in the breeding of plateau cattle.

The application provides a molecular marker related to sheep immunity traits and application thereof. The application uses a method for detecting a PLEKHH2 gene SNP site of Lake sheep by combining DNA pool sequencing with KASPar technology. A primer is designed according to a PLEKHH2 gene sequence, DNA is extracted from sheep blood, and PCR amplification, DNA sequencing and sequence analysis are carried out, so that a C / G polymorphic site at the 368th position of the amplified fragment is found. Further, KASPar primers are used to detect the polymorphic site of 889 Lake sheep and to establish a least square model, and correlation analysis is carried out on the genotype and immunity trait indexes, so that it is found that the site is significantly related to the platelet count (PLT) and the mean corpuscular hemoglobin concentration (MCHC) of sheep. Through detection of the molecular marker of the application, the application can be used in marker-assisted disease-resistant breeding of sheep and can accelerate the breeding process of sheep.

To provide a reference transcriptome-wide expression profile that takes into account the temporal changes in gene expression in platelets. [Solution] A method for creating transcriptome-wide expression profiles of biological samples and identifying biomarkers that can be used for diagnosing diseases, monitoring their onset, monitoring their progression, and evaluating their recovery is disclosed herein. These biomarkers can also be used to establish and evaluate treatment regimens.

This invention provides a method for determining the biological age, risk of death, and / or probability of healthy lifespan of a dog; the method comprising: a) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using the levels of one or more biomarkers selected from one or more samples obtained from the dog, wherein the one or more biomarkers are selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, hemoglobin, hematocrit, mean corpuscular hemoglobin, serum glucose, mean corpuscular volume, serum globulin, serum calcium, platelet count, and / or red blood cell count; and b) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using DNA methylation profiles from the dog.

This specimen measurement device for measuring a blood specimen collected from a subject includes: an electrical detection unit (120) for detecting an electrical signal corresponding to a cell; an optical detection unit (110) for detecting an optical signal corresponding to the cell; a hemoglobin detection unit (130) for detecting an optical signal corresponding to a blood pigment; a preparation unit (162); and an analysis unit for analyzing measurement data and providing an analysis result. The preparation unit (162) prepares a measurement sample PAB for detecting platelet aggregation by the optical detection unit (110) in accordance with a measurement order including a measurement instruction for a measurement item CBC or measurement items CBC and DIFF. The analysis unit analyzes measurement data obtained by measuring the measurement sample PAB, and provides an analysis result relating to platelet aggregation.

An example system includes a chamber to hold a mixture that includes a whole blood sample from a patient, a light source to illuminate the mixture in the chamber, a detector to detect light from the light source transmitted through the mixture in the chamber, and one or more processing devices to determine, based on the light detected by the detector, a platelet aggregation value of the whole blood sample that is substantially independent of a hematocrit of the whole blood sample.